Cardiovascular Diabetology最新文献

{"title":"Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).","authors":"Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Claudio Montalto, Elayne Kelen de Oliveira, Francesco Angeli, Mateusz Orzalkiewicz, Margherita Fabroni, Verdiana Galli, Nurcan Baydaroglu, Francesca Di Lenarda, Pasquale Policastro, Carlo Terrone, Davide Ausiello, Giose Vincelli, Matteo Casenghi, Lucia Scisciola, Raffaele Marfella, Felice Gragnano, Edoardo Conte, Dario Pellegrini, Alfonso Ielasi, Daniele Andreini, Jacopo Andrea Oreglia, Paolo Calabrò, Antonio L Bartorelli, Tullio Palmerini, Francesco Saia, Flavio Ribichini, Michelangela Barbieri, Marc Vanderheyden, Carmine Pizzi, Emanuele Barbato","doi":"10.1186/s12933-025-02773-x","DOIUrl":"10.1186/s12933-025-02773-x","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI) is associated with significantly worse outcomes, leading to increased short- and long-term mortality. We sought to evaluate the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the risk of AKI in patients with type 2 diabetes mellitus (T2DM) and severe aortic stenosis (AS) undergoing TAVI.</p><p><strong>Methods: </strong>Multicenter international registry of consecutive T2DM patients with severe AS undergoing TAVI between 2021 and 2024. The study population was stratified by the presence of chronic kidney disease (CKD), defined according to the KDIGO guideline, and anti-diabetic therapy at hospital admission (SGLT2i versus no-SGLT2i users). AKI was defined according to the Valve Academy Research Consortium 3 (VARC-3) criteria.</p><p><strong>Results: </strong>The study population consisted of 514 patients stratified into those without CKD (n = 226, 44%), of whom 43 (19%) were treated with SGLT2i, and 288 (56%) with CKD, of whom 71 (24.7%) were on SGLT2i treatment. The median age was 81 [77-84] years, and 60.1% were males. SGLT2i use did not impact renal function in patients without CKD, with AKI occurring in 7.1% of the cases, regardless of SGLT2i use. Among CKD patients, AKI occurred more frequently in no-SGLT2i users compared to those receiving SGLT2i (19.8% versus 8.5%, p = 0.027), with a significant increase in post-TAVI and discharge serum creatinine values for no-SGLT2i users (p = 0.001 after TAVI and p < 0.001 at hospital discharge). Only in the CKD group, the use of SGLT2i was identified as an independent predictor of a lower rate of AKI (OR 0.70, 95%CI 0.42-0.91, p = 0.014). Patients who developed AKI had a higher incidence of major adverse cardiovascular events during follow-up, regardless of CKD (p < 0.025 for both groups).</p><p><strong>Conclusion: </strong>In diabetic patients with CKD undergoing TAVI, SGLT2i therapy was associated with a lower occurrence of AKI compared to those not treated with SGLT2i, suggesting a potential nephroprotective effect in this high-risk population.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"221"},"PeriodicalIF":8.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease in women with type 1 diabetes: a narrative review and insights from a population-based cohort analysis.","authors":"Alex Mesa, Josep Franch-Nadal, Elena Navas, Dídac Mauricio","doi":"10.1186/s12933-025-02791-9","DOIUrl":"10.1186/s12933-025-02791-9","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) remains the leading cause of mortality among people with type 1 diabetes (T1D), with cardiovascular mortality rates 2-5 times higher than in the general population. A concerning sex disparity exists within this high-risk population, as the cardioprotective advantage typically observed in women without diabetes appears attenuated or eliminated in individuals with T1D. This disparity is evident across the CVD spectrum, including coronary artery disease, stroke, heart failure, and cardiovascular mortality, with women consistently experiencing an excess burden of disease. These differences are particularly pronounced in women with early-onset T1D, leading to a substantial loss of life-years-approximately 18 years for women compared to 14 for men. Several factors may contribute to this sex disparity. First, the effect of hyperglycemia on CVD appears to have a sex-based differential impact and women with T1D often demonstrate more difficulties to achieve optimal glycemic control. Second, although women with T1D generally exhibit a more favorable CVD risk factor profile than men with T1D, the presence of hypertension, smoking or diabetic kidney disease seem to have a strong impact on CVD in women. Diabetes also appears to diminish sex-based differences in lipid metabolism, and a trend towards increased obesity rates among women with T1D has been observed. Lastly, female-specific factors, which are more prevalent in T1D, exacerbate cardiovascular risk. These include premature menopause, pregnancy-related disorders (such as preeclampsia), polycystic ovary syndrome, and autoimmune diseases, which disproportionately affect women. This narrative review examines the epidemiological evidence highlighting the aspects regarding the excess risk of CVD in women with T1D and evaluates sex disparities in both traditional and female-specific risk factors. Finally, we include a sex-based analysis from the Catalan Registry, which highlights the critical need for greater awareness and enhanced early detection and management of CVD risk factors in this population.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"217"},"PeriodicalIF":8.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the atherogenic index of plasma and incident hypertension across different blood pressure states: a national cohort study.","authors":"Degang Mo, Peng Zhang, Miao Zhang, Hongyan Dai, Guoan Wang","doi":"10.1186/s12933-025-02775-9","DOIUrl":"10.1186/s12933-025-02775-9","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a major public health concern, making effective preventive strategies essential. The atherogenic index of plasma (AIP), a new lipid metabolic index that is associated with insulin resistance and cardiovascular diseases. However, the association between AIP and the incidence of hypertension remains unexplored. To address this knowledge gap, we designed a large-scale retrospective cohort study to investigate the association between AIP and the occurrence of hypertension across different blood pressure (BP) states, including individuals with normal BP and those with elevated BP.</p><p><strong>Methods: </strong>This retrospective cohort study used data from the China Health and Retirement Longitudinal Study (CHARLS) involving participants aged 45 and older, assessed in 2011 and followed up in 2020. AIP was calculated using the logarithmic ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C). Logistic regression models, restricted cubic splines models, and threshold analyses were employed to examine the relationship between AIP and the incidence of hypertension. Receiver Operating Characteristic analysis was utilized to assess the ability of AIP to predict the incidence of hypertension. Subgroup analyses were conducted across various demographic and health-related factors. Sensitivity analyses were employed to address biases arising from self-reported data.</p><p><strong>Results: </strong>Among 6540 participants, 1909 (29.19%) developed hypertension over nine years. The AIP is an independent risk factor for the development of hypertension, with an adjusted odds ratio of 1.84 [95% confidence interval (CI) 1.41-2.39, p < 0.001] in individuals with normal BP and 1.88 (95% CI 1.40-2.52, p < 0.001) in those with elevated BP. A nonlinear relationship between AIP and the incidence of hypertension was identified in both normal BP and elevated BP population. AIP has a better predictive ability for the occurrence of hypertension compared to the single indicators of TG and HDL-C. Age significantly impacted AIP's predictive value, especially in those aged 45 to 60 in normal BP population. Sensitivity analyses further validated the nonlinear relationship between AIP and the occurrence of hypertension.</p><p><strong>Conclusions: </strong>AIP is a significant predictor of hypertension, demonstrating a nonlinear association with its occurrence in normal BP and elevated BP population.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"219"},"PeriodicalIF":8.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk profile in subjects with diabetes: Is SCORE2-Diabetes reliable?","authors":"Sabrina Scilletta, Maurizio Di Marco, Nicoletta Miano, Stefania Capuccio, Marco Musmeci, Giosiana Bosco, Francesco Di Giacomo Barbagallo, Marina Martedì, Francesca La Rocca, Alessio Vitale, Roberto Scicali, Salvatore Piro, Antonino Di Pino","doi":"10.1186/s12933-025-02769-7","DOIUrl":"10.1186/s12933-025-02769-7","url":null,"abstract":"<p><strong>Background: </strong>People living with type 2 diabetes (T2D) are at a two- to four-fold higher risk of developing cardiovascular disease (CVD) compared with those without T2D, making early assessment of their CV risk essential. European Society of Cardiology (ESC) has developed a new model to estimate 10-year CV risk in people with T2D aged ≥ 40 years: SCORE2-Diabetes. Despite its advantages, several aspects remain to be clarified. This study evaluated the association between CV risk stratified by SCORE2-Diabetes and early CV damage assessed through arterial stiffness, intima-media thickness (IMT), and carotid atherosclerosis. Additionally, it examined the agreement between risk stratification by SCORE2 and SCORE2-Diabetes and their concordance with vascular damage.</p><p><strong>Methods: </strong>Pulse wave velocity (PWV), IMT, and carotid atherosclerosis were assessed in 179 individuals with T2D aged 40-69 years, categorized into SCORE2-Diabetes risk groups: Low (n = 20), Moderate (n = 29), High (n = 44), and very high (n = 37). Patients with a history of atherosclerotic cardiovascular disease (ASCVD) or severe target organ damage (TOD) constituted another group (ASCVD/TOD, n = 49).</p><p><strong>Results: </strong>PWV was significantly increased from Low to very high and ASCVD/TOD groups (7.2 ± 1.1, 8.7 ± 1.9, 9.8 ± 2.3, 12.8 ± 5.1 and 11.5 ± 3.8 m/s, respectively). Similarly, IMT showed a stepwise increase with risk class (0.68 ± 0.11, 0.78 ± 0.13, 0.83 ± 0.12, 0.86 ± 0.19 and 0.87 ± 0.15 mm, respectively). Patients in very high or ASCVD/TOD group showed a higher prevalence of carotid atherosclerosis than other groups (0%, 17.24%, 11.40%, 37.83% and 40.81%, respectively). No significant differences were found between the very high and ASCVD/TOD groups in any parameter. The correlation between PWV values and increasing CV risk was stronger for SCORE2-Diabetes than for SCORE2. ROC curve analysis showed SCORE2-Diabetes had superior predictive performance for carotid atherosclerosis and high PWV compared to SCORE2 (p = 0.048).</p><p><strong>Conclusions: </strong>Higher PWV, IMT, and carotid atherosclerosis prevalence were associated with increasing CV risk stratified by SCORE2-Diabetes, with no significant differences between the very high and ASCVD/TOD groups. SCORE2-Diabetes demonstrated a better identification of preclinical vascular damage compared to SCORE2, supporting its use as a reliable tool for identifying vascular damage in T2D patients without ASCVD or TOD.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"222"},"PeriodicalIF":8.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of diabetes mellitus on delirium onset: a systematic review and meta-analysis.","authors":"Klara Komici, Carlo Fantini, Gaetano Santulli, Leonardo Bencivenga, Grazia Daniela Femminella, Germano Guerra, Pasquale Mone, Giuseppe Rengo","doi":"10.1186/s12933-025-02782-w","DOIUrl":"10.1186/s12933-025-02782-w","url":null,"abstract":"<p><strong>Background: </strong>Delirium may develop in association with an underlying cardiovascular or cerebrovascular disease and complicates one out of three medical admissions representing a significant economic burden for healthcare systems. However, a clear relationship between delirium onset and diabetes mellitus has not been clarified. The purpose of this study was to explore the association between DM and delirium with the following aims: (a) to assess the incidence of delirium among DM patients (b) to assess the risk of delirium onset in patients with DM (c) to assess the role of anti-diabetic drugs on delirium onset.</p><p><strong>Methods: </strong>MEDLINE, Scopus, and Web of Science and ClinicalTrials.gov were searched from inception up to 30th of December 2024. Studies reporting the incidence of delirium in diabetic patients, delirium events in diabetic patients compared to non- diabetic patients, and the role of antidiabetic drugs on delirium development were considered.</p><p><strong>Results: </strong>The pooled incidence of delirium resulted 29% (95% CI 26.0%- 33.0% I2 = 99.6%). The OR for developing delirium resulted: 1.78 (95% CI 1.59-1.99 i2 = 88.3%) Intranasal insulin administration compared to placebo groups was characterized by a RR = 0.34 (95% CI 0.23-0.52). Metformin use compared to non-metformin use in diabetic patients was characterized by lower RR for delirium: pooled RR = 0.71 (95% CI 0.59-0.85, I2 = 84.8%).</p><p><strong>Conclusions: </strong>The incidence of delirium in patients with diabetes is about 29% and patients with diabetes have higher odds of delirium. Chronic use of metformin, and intranasal insulin administration before surgery may offer benefits in the prevention of delirium. These findings are characterized by significant heterogeneity which hampers their interpretation. Future research for developing diabetes-specific delirium screening protocols, and evidence-based preventive interventions is needed.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"216"},"PeriodicalIF":8.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of glycemic status on myocardial deformation and microvascular function in uncomplicated pediatric type 1 diabetes mellitus: cardiac magnetic resonance imaging.","authors":"Lu Zhang, Shan Huang, Xueming Li, Zhi Yang, Pengfei Ye, Ran Sun, Huayan Xu, Rong Xu, Meng Zhang, Ying Liu, Chuanjie Yuan, Jin Wu, Yingkun Guo","doi":"10.1186/s12933-025-02757-x","DOIUrl":"10.1186/s12933-025-02757-x","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease remains the leading cause of morbidity and mortality among individuals with type 1 diabetes mellitus (T1DM). Individuals with hyperglycemia are at great risk of cardiovascular complications. This study investigated the impact of glycemic control on left ventricular (LV) microvascular perfusion and myocardial deformation in uncomplicated pediatric T1DM using cardiac magnetic resonance (CMR) imaging.</p><p><strong>Methods: </strong>A total of 100 uncomplicated pediatric patients with T1DM and 35 controls were enrolled and underwent 3.0 T CMR examinations. Patients were divided into two groups according to HbA1c levels of 7.0% (HbA1c < 7.0%, n = 25; HbA1c ≥ 7.0%, n = 75). Subclinical systolic and diastolic function were evaluated using peak strain and strain rate based on myocardial deformation analysis. Myocardial perfusion upslope and maximum signal intensity (MaxSI) were assessed via first-pass perfusion imaging at rest. Multivariable linear regression analyses identified the independent factors of reduced myocardial perfusion and deformation in T1DM patients.</p><p><strong>Results: </strong>Among the three groups, longitudinal peak diastolic strain rate (PDSR) deteriorated gradually from controls through patients with HbA1c < 7.0% to patients with HbA1c ≥ 7.0% (all p < 0.05). Upslope in patients with HbA1c ≥ 7.0% was decreased compared to patients with HbA1c < 7.0% (p = 0.007) and controls (p < 0.001). Compared to controls, both MaxSI and circumferential PDSR were reduced in patients with HbA1c ≥ 7.0% (p = 0.025 and 0.016, respectively), but not in patients with HbA1c < 7.0% (p = 0.566 and 0.379, respectively). In multivariable analysis, elevated HbA1c level was independently associated with reduced upslope (β = - 2.53, p < 0.001) and longitudinal PDSR (β = - 0.02, p = 0.007). When the perfusion indices were included in the multivariable analysis for diastolic dysfunction, upslope (β = 0.10, p = 0.016) and MaxSI (β = - 0.02, p = 0.006) were associated with reduced longitudinal PDSR.</p><p><strong>Conclusion: </strong>Pediatric T1DM with higher HbA1c showed worse myocardial perfusion and subclinical diastolic dysfunction. Microvascular dysfunction was associated independently with cardiac dysfunction.</p><p><strong>Trial registration: </strong>retrospectively registered ChiCTR2100043799.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"215"},"PeriodicalIF":8.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.","authors":"Sara W Quist, Alexander V van Schoonhoven, Stephan J L Bakker, Michał Pochopień, Maarten J Postma, Jeanni M T van Loon, Jeroen H J Paulissen","doi":"10.1186/s12933-025-02752-2","DOIUrl":"10.1186/s12933-025-02752-2","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"212"},"PeriodicalIF":8.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.","authors":"James L Jr Januzzi, Naveed Sattar, Muthiah Vaduganathan, Craig A Magaret, Rhonda F Rhyne, Yuxi Liu, Serge Masson, Javed Butler, Michael K Hansen","doi":"10.1186/s12933-025-02779-5","DOIUrl":"10.1186/s12933-025-02779-5","url":null,"abstract":"<p><strong>Background: </strong>Individuals with diabetic kidney disease (DKD) often suffer cardiac and kidney events. We sought to develop an accurate means by which to stratify risk in DKD.</p><p><strong>Methods: </strong>Clinical variables and biomarkers were evaluated for their ability to predict the adjudicated primary composite endpoint of CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) by 3 years. Using machine learning techniques, a parsimonious risk algorithm was developed.</p><p><strong>Results: </strong>The final model included age, body-mass index, systolic blood pressure, and concentrations of N-terminal pro-B type natriuretic peptide, high sensitivity cardiac troponin T, insulin-like growth factor binding protein-7 and growth differentiation factor-15. The model had an in-sample C-statistic of 0.80 (95% CI = 0.77-0.83; P < 0.001). Dividing results into low, medium and high risk categories, for each increase in level the hazard ratio increased by 3.43 (95% CI = 2.72-4.32; P < 0.001). Low risk scores had negative predictive value of 94%, while high risk scores had positive predictive value of 58%. Higher values were associated with shorter time to event (log rank P < 0.001). Rising values at 1 year predicted higher risk for subsequent DKD events. Canagliflozin treatment reduced score results by 1 year with consistent event reduction across risk levels. Accuracy of the risk model was validated in separate cohorts from CREDENCE and the generally lower risk Canagliflozin Cardiovascular Assessment Study.</p><p><strong>Conclusions: </strong>We describe a validated risk algorithm that accurately predicts cardio-kidney outcomes across a broad range of baseline risk.</p><p><strong>Trial registration: </strong>CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; NCT02065791) and CANVAS (Canagliflozin Cardiovascular Assessment Study; NCT01032629/NCT01989754).</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"213"},"PeriodicalIF":8.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Insights into the complex relationship between triglyceride glucose-waist height ratio index, mean arterial pressure, and cardiovascular disease: a nationwide prospective cohort study.","authors":"Jie Xu, Dihui Cai, Yuheng Jiao, Yingying Liao, Yinyin Shen, Yunli Shen, Wei Han","doi":"10.1186/s12933-025-02728-2","DOIUrl":"10.1186/s12933-025-02728-2","url":null,"abstract":"","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"214"},"PeriodicalIF":8.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?","authors":"Francesca Cinti, Renzo Laborante, Luigi Cappannoli, Cassandra Morciano, Shawn Gugliandolo, Alfredo Pontecorvi, Francesco Burzotta, Maria Donniacuo, Donato Cappetta, Giuseppe Patti, Andrea Giaccari, Domenico D'Amario","doi":"10.1186/s12933-025-02767-9","DOIUrl":"https://doi.org/10.1186/s12933-025-02767-9","url":null,"abstract":"<p><p>The rising prevalence of Type 2 diabetes (T2D) has been closely associated with an increased incidence of cardiovascular diseases, particularly heart failure with preserved ejection fraction (HFpEF). Cardiometabolic disturbances in T2D, such as insulin resistance, hyperglycemia, and dyslipidemia, contribute to both microvascular and macrovascular complications, thereby intensifying the risk of heart failure. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed as glucose-lowering agents for T2D, have demonstrated promising cardiovascular benefits in patients with heart failure, including those with preserved ejection fraction (HFpEF), regardless of T2D status. These benefits include reduced heart failure hospitalization rates and improvements in various metabolic parameters. This review aims to critically examine the effects of SGLT2i on cardiac metabolism in HFpEF, evaluating whether the observed benefits can truly be attributed to their impact on myocardial energy regulation or whether they represent other, potentially confounding, mechanisms. We will focus on the key metabolic processes possibly modulated by SGLT2i, including myocardial glucose utilization, fatty acid oxidation, and mitochondrial function, and explore their effects on heart failure pathophysiology. Additionally, we will address the role of SGLT2i in other pathogenetic factors involved in HFpEF, such as sodium and fluid balance, inflammation, and fibrosis, and question the extent to which these mechanisms contribute to the observed clinical benefits. By synthesizing the current evidence, this review will provide an in-depth analysis of the mechanisms through which SGLT2i may influence cardiac metabolism in HFpEF, assessing whether their effects are supported by robust scientific data or remain speculative. We will also discuss the potential for personalized treatment strategies, based on individual patient characteristics, to optimize the therapeutic benefits of SGLT2i in managing both T2D and cardiovascular risk. This review seeks to clarify the true clinical utility of SGLT2i in the management of cardiometabolic diseases and HFpEF, offering insights into their role in improving long-term cardiovascular outcomes.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":"24 1","pages":"208"},"PeriodicalIF":8.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}